168 related articles for article (PubMed ID: 1992877)
21. [A retrospective analysis of the treatment results in Hodgkin's disease in a radiotherapy clinic].
Mjaaland I; Ganser D; Freitag EM; Bohndorf W
Strahlenther Onkol; 1994 Sep; 170(9):516-23. PubMed ID: 7524173
[TBL] [Abstract][Full Text] [Related]
22. Definition of bulky disease in early stage Hodgkin lymphoma in computed tomography era: prognostic significance of measurements in the coronal and transverse planes.
Kumar A; Burger IA; Zhang Z; Drill EN; Migliacci JC; Ng A; LaCasce A; Wall D; Witzig TE; Ristow K; Yahalom J; Moskowitz CH; Zelenetz AD
Haematologica; 2016 Oct; 101(10):1237-1243. PubMed ID: 27390360
[TBL] [Abstract][Full Text] [Related]
23. Treatment for relapse in stage I/II Hodgkin's lymphoma after initial single-modality treatment.
Rueda A; Olmos D; Viciana R; Alba E
Clin Lymphoma Myeloma; 2006 Mar; 6(5):389-92. PubMed ID: 16640815
[TBL] [Abstract][Full Text] [Related]
24. Erythrocyte sedimentation rate and C-reactive protein in the evaluation of disease activity and severity in polymyalgia rheumatica: a prospective follow-up study.
Cantini F; Salvarani C; Olivieri I; Macchioni L; Ranzi A; Niccoli L; Padula A; Boiardi L
Semin Arthritis Rheum; 2000 Aug; 30(1):17-24. PubMed ID: 10966209
[TBL] [Abstract][Full Text] [Related]
25. Clinical significance of prognosis using the neutrophil-lymphocyte ratio and erythrocyte sedimentation rate in patients undergoing radical nephroureterectomy for upper urinary tract urothelial carcinoma.
Sung HH; Jeon HG; Jeong BC; Seo SI; Jeon SS; Choi HY; Lee HM
BJU Int; 2015 Apr; 115(4):587-94. PubMed ID: 24947340
[TBL] [Abstract][Full Text] [Related]
26. Tumour burden at diagnosis as the main clinical predictor of cell resistance in patients with early stage, favourable Hodgkin lymphoma treated with VBM chemotherapy plus radiotherapy.
Gobbi PG; Bergonzi M; Bassi E; Merli F; Coriani C; Federico M
Hematol Oncol; 2013 Sep; 31(3):151-5. PubMed ID: 23108910
[TBL] [Abstract][Full Text] [Related]
27. The clinical relevance of plasma viscosity in Hodgkin's disease.
Akhtar N; Thompson J; Durrant ST; Angel CA; Lauder I; Wood JK
Clin Lab Haematol; 1991; 13(1):1-8. PubMed ID: 2060259
[TBL] [Abstract][Full Text] [Related]
28. Prognostic factors for patients relapsing after radiotherapy for early-stage Hodgkin's disease.
Roach M; Brophy N; Cox R; Varghese A; Hoppe RT
J Clin Oncol; 1990 Apr; 8(4):623-9. PubMed ID: 2313331
[TBL] [Abstract][Full Text] [Related]
29. Nodular lymphocyte predominant Hodgkin lymphoma: a Lymphoma Study Association retrospective study.
Lazarovici J; Dartigues P; Brice P; Obéric L; Gaillard I; Hunault-Berger M; Broussais-Guillaumot F; Gyan E; Bologna S; Nicolas-Virelizier E; Touati M; Casasnovas O; Delarue R; Orsini-Piocelle F; Stamatoullas A; Gabarre J; Fornecker LM; Gastinne T; Peyrade F; Roland V; Bachy E; André M; Mounier N; Fermé C
Haematologica; 2015 Dec; 100(12):1579-86. PubMed ID: 26430172
[TBL] [Abstract][Full Text] [Related]
30. Contribution of involved-field radiotherapy to survival in patients with relapsed or refractory Hodgkin lymphoma undergoing autologous stem cell transplantation.
Eroglu C; Kaynar L; Orhan O; Keklik M; Sahin C; Yildiz OG; Mentes S; Kurnaz F; Aslan D; Sivgin S; Soyuer S; Eser B; Cetin M; Unal A
Am J Clin Oncol; 2015 Feb; 38(1):68-73. PubMed ID: 23563207
[TBL] [Abstract][Full Text] [Related]
31. Intercurrent death after Hodgkin disease therapy in radiotherapy and adjuvant MOPP trials.
Hancock SL; Hoppe RT; Horning SJ; Rosenberg SA
Ann Intern Med; 1988 Aug; 109(3):183-9. PubMed ID: 3291657
[TBL] [Abstract][Full Text] [Related]
32. Improved survival in patients with limited stage IIIA Hodgkin's disease treated with combined radiation therapy and chemotherapy.
Marcus KC; Kalish LA; Coleman CN; Shulman LN; Rosenthal DS; Canellos GP; Mauch PM
J Clin Oncol; 1994 Dec; 12(12):2567-72. PubMed ID: 7989930
[TBL] [Abstract][Full Text] [Related]
33. [A analysis of the outcome and prognostic factors in 415 patients with Hodgkin lymphoma].
Tao Y; Kang S; Zhou L; Shi Y; Li Y; Sun Y
Zhonghua Zhong Liu Za Zhi; 2015 Jun; 37(6):466-71. PubMed ID: 26463153
[TBL] [Abstract][Full Text] [Related]
34. Site of relapse after chemotherapy alone for stage I and II Hodgkin's disease.
Shahidi M; Kamangari N; Ashley S; Cunningham D; Horwich A
Radiother Oncol; 2006 Jan; 78(1):1-5. PubMed ID: 16309770
[TBL] [Abstract][Full Text] [Related]
35. Relapsed hodgkin lymphoma in older patients: a comprehensive analysis from the German hodgkin study group.
Böll B; Goergen H; Arndt N; Meissner J; Krause SW; Schnell R; von Tresckow B; Eichenauer DA; Sasse S; Fuchs M; Behringer K; Klimm BC; Naumann R; Diehl V; Engert A; Borchmann P
J Clin Oncol; 2013 Dec; 31(35):4431-7. PubMed ID: 24190119
[TBL] [Abstract][Full Text] [Related]
36. Serum lactate dehydrogenase level as a prognostic factor in Hodgkin's disease.
García R; Hernández JM; Caballero MD; González M; Galende J; del Cañizo MC; Vázquez L; San Miguel JF
Br J Cancer; 1993 Dec; 68(6):1227-31. PubMed ID: 8260377
[TBL] [Abstract][Full Text] [Related]
37. Comparison of 36 Gy, 20 Gy, or No Radiation Therapy After 6 Cycles of EBVP Chemotherapy and Complete Remission in Early-Stage Hodgkin Lymphoma Without Risk Factors: Results of the EORT-GELA H9-F Intergroup Randomized Trial.
Thomas J; Fermé C; Noordijk EM; Morschhauser F; Girinsky T; Gaillard I; Lugtenburg PJ; André M; Lybeert MLM; Stamatoullas A; Beijert M; Hélias P; Eghbali H; Gabarre J; van der Maazen RWM; Jaubert J; Bouabdallah K; Boulat O; Roesink JM; Christian B; Ong F; Bordessoule D; Tertian G; Gonzalez H; Vranovsky A; Quittet P; Tirelli U; de Jong D; Audouin J; Aleman BMP; Henry-Amar M
Int J Radiat Oncol Biol Phys; 2018 Apr; 100(5):1133-1145. PubMed ID: 29229324
[TBL] [Abstract][Full Text] [Related]
38. Outcome of patients experiencing progression or relapse after primary treatment with two cycles of chemotherapy and radiotherapy for early-stage favorable Hodgkin's lymphoma.
Sieniawski M; Franklin J; Nogova L; Glossmann JP; Schober T; Nisters-Backes H; Diehl V; Josting A
J Clin Oncol; 2007 May; 25(15):2000-5. PubMed ID: 17420510
[TBL] [Abstract][Full Text] [Related]
39. The contribution of clinical trials to the treatment of patients with early stages of Hodgkin's disease.
Tubiana M; Cosset JM; Carde P; Henry-Amar M; Hayat M; Amiel JL
Drugs Exp Clin Res; 1986; 12(1-3):105-12. PubMed ID: 3732047
[TBL] [Abstract][Full Text] [Related]
40. Inflammation marker ESR is effective in predicting outcome of diffuse large B-cell lymphoma.
Wu S; Zhou Y; Hua HY; Zhang Y; Zhu WY; Wang ZQ; Li J; Gao HQ; Wu XH; Lu TX; Hua D
BMC Cancer; 2018 Oct; 18(1):997. PubMed ID: 30340560
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
